FDA Maps 4 Approval Pathways For Blood Products

Regulatory affairs teams managing blood product portfolios operate across four distinct FDA CBER approval frameworks, each carrying separate submission requirements, supporting documentation standards, and post-approval obligations. Understanding which pathway governs a given product class is a prerequisite for compliant lifecycle management.

Fractionated plasma products, including Alpha-1-Proteinase Inhibitor, Antihemophilic Factor, Antithrombin, C1 Esterase Inhibitor, Coagulation Factors, Fibrin, Fibrinogen, Immune Globulins, Protein C, and Thrombin, are regulated under Biologics License Applications (BLAs). Blood donor screening tests for infectious diseases and blood grouping and phenotyping reagents fall within the same BLA framework, placing them under CBER's biologics oversight structure.

Collection solutions used in blood and plasma donation are classified as drugs and require New Drug Applications (NDAs) under CBER jurisdiction. This distinction is operationally significant: NDA holders must align post-approval change management with 21 CFR Part 314 rather than the biologics regulations governing BLA holders.

On the device side, CBER administers two parallel tracks. Blood donor testing equipment is subject to Premarket Approval (PMA), the most rigorous device pathway, requiring demonstration of safety and effectiveness. A broader range of blood banking equipment, including blood establishment computer software, transfer devices, collection systems, separators, culture bottles, and fluid warmers, clears through the 510(k) substantial equivalence route. For QA directors overseeing blood establishment computer software validation, the 510(k) clearance status of a given system directly informs the validation framework and change-control obligations under 21 CFR Part 211 and applicable CBER guidance.

CBER maintains publicly accessible supporting documentation for each pathway: licensed BLA products, cleared 510(k) submissions, approved PMAs including Humanitarian Device Exemptions, and complete NDA and ANDA submission lists. These resources serve as reference anchors during pre-submission planning, inspection preparation, and gap assessments against current approval standards.

For teams preparing BLA supplements or PMA amendments, CBER's published process guidance for each pathway, including the IND process for investigational products, provides the procedural baseline against which submission packages should be benchmarked before filing.

As CBER continues to update its approved product databases, regulatory affairs leads should treat these listings as living references rather than static inventories, particularly when assessing predicate device eligibility for 510(k) submissions or confirming the current licensure status of plasma-derived biologics.

Source: FDA Center for Biologics Evaluation and Research via FDA.gov RSS Feed, 8 September 2026.